When looking at correlation of changes in PET/SPECT findings with changes in glycemic control, (i) there was no correlation between increase in DRD2/3 availability (123I‐IBZM BP) in striatum with decrease in FPG at 3 years post‐RYGB surgery for obesity (with unknown number having T2DM at baseline)52; while (ii) greater reduction in DRD2/3 availability (18F‐fallypride BP) in caudate, putamen, and substantial nigra correlated with greater decrease in FPG 10 days post‐VLCD for obesity (only 7% with T2DM).35 The gene discussed is DRD2; the disease is Obesity.